SPRUCE BIOSCIENCES, INC. short interest in 2022
In 2022, SPRUCE BIOSCIENCES, INC.'s disclosed short interest ran from 2.15% of shares outstanding on 14 Jan 2022 to 2.90% on 30 Dec 2022, a change of +0.75 percentage points. The year's high was 2.90% on 30 Dec 2022 and its low 0.26% on 31 Aug 2022, averaging 1.46% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.80 days on 30 Dec 2022. Full history: SPRUCE BIOSCIENCES, INC..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 2.15% (14 Jan 2022)
- End of year
- 2.90% (30 Dec 2022)
- Change
- +0.75 pp
- High
- 2.90% (30 Dec 2022)
- Low
- 0.26% (31 Aug 2022)
- Average
- 1.46%
- Highest days to cover
- 13.80 (30 Dec 2022)
- SEC filings marked
- 9
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 2.15% | 1.00 | results (8-K) |
| 31 Jan 2022 | 1.93% | 1.00 | |
| 15 Feb 2022 | 1.78% | 2.04 | |
| 28 Feb 2022 | 1.70% | 2.54 | |
| 15 Mar 2022 | 1.40% | 2.55 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 1.33% | 1.82 | |
| 14 Apr 2022 | 1.61% | 5.08 | |
| 29 Apr 2022 | 1.65% | 2.39 | |
| 13 May 2022 | 1.64% | 3.55 | 10-Q filed, results (8-K) |
| 31 May 2022 | 1.78% | 5.12 | |
| 15 Jun 2022 | 1.83% | 1.00 | |
| 15 Aug 2022 | 0.31% | 2.37 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 0.26% | 2.72 | |
| 15 Sep 2022 | 0.32% | 2.37 | |
| 30 Sep 2022 | 0.26% | 2.53 | |
| 14 Oct 2022 | 0.36% | 2.97 | |
| 15 Nov 2022 | 1.40% | 7.76 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 2.13% | 3.60 | |
| 15 Dec 2022 | 2.50% | 11.21 | |
| 30 Dec 2022 | 2.90% | 13.80 |
See also: SPRUCE BIOSCIENCES, INC.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.